The societal burden of osteoporosis in Sweden
- 30 June 2007
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 40 (6), 1602-1609
- https://doi.org/10.1016/j.bone.2007.02.027
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Cost effectiveness of raloxifene in the treatment of osteoporosis in SwedenPharmacoEconomics, 2004
- Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Value in Health, 2004
- Cost effectiveness of alendronate for the treatment of male osteoporosis in SwedenBone, 2004
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- The cost of a hip fracture: Estimates for 1,709 patients in SwedenActa Orthopaedica, 1997
- Cost-effectiveness of Fracture Prevention in Established OsteoporosisScandinavian Journal of Rheumatology, 1996
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992
- Increased Hip-Fracture Incidence in the County of Östergötland, Sweden, 1940–1986, with Forecasts up to the Year 2000: An Epidemiological StudyInternational Journal of Epidemiology, 1991